Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas

UnknownOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
LeiomyomaLeiomyosarcoma
Interventions
PROCEDURE

Biopsy and peripheral blood collection

"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."

Trial Locations (4)

30120

RECRUITING

Hospital Universitario Virgen de la Arrixaca, El Palmar

30202

RECRUITING

Complejo Hospitalario Universitario de Cartagena, Cartagena

46009

RECRUITING

Instituto Valenciano de Oncología, Valencia

46026

RECRUITING

Hospital Universitario y Politécnico La Fe, Valencia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Igenomix

INDUSTRY

NCT04214457 - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas | Biotech Hunter | Biotech Hunter